Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$27.16 USD
+0.74 (2.80%)
Updated Jul 26, 2024 09:50 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
NTLA 27.16 +0.74(2.80%)
Will NTLA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTLA
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Other News for NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
7 Biotech Stocks to Keep on Your Clinical Radar
3 Gene Editing Stocks That Could Grow Your Wealth
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition